Ad is loading...
EPLCX
Price
$24.13
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
VVIAX
Price
$69.72
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
Ad is loading...

EPLCX vs VVIAX

Header iconEPLCX vs VVIAX Comparison
Open Charts EPLCX vs VVIAXBanner chart's image
NYLI Epoch U.S. Equity Yield
Price$24.13
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index Adm
Price$69.72
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
EPLCX vs VVIAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
EPLCX vs. VVIAX commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EPLCX is a Buy and VVIAX is a StrongBuy.

FUNDAMENTALS
Fundamentals
VVIAX has more cash in the bank: 184B vs. EPLCX (1.09B). VVIAX pays higher dividends than EPLCX: VVIAX (2.36) vs EPLCX (2.22). EPLCX was incepted earlier than VVIAX: EPLCX (16 years) vs VVIAX (24 years). EPLCX is a more actively managed with annual turnover of: 19.00 vs. VVIAX (10.00). VVIAX has a lower initial minimum investment than EPLCX: VVIAX (3000) vs EPLCX (1000000). EPLCX (26.54) and VVIAX (26.09) have marching annual gain over last year. VVIAX (53.09) and EPLCX (51.65) have equivalent 5 years return.
EPLCXVVIAXEPLCX / VVIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence16 years24 years-
Gain YTD23.76119.672121%
Front LoadN/AN/A-
Min. Initial Investment1000000300033,333%
Min. Initial Investment IRAN/AN/A-
Net Assets1.09B184B1%
Annual Yield % from dividends2.222.3694%
Returns for 1 year26.5426.09102%
Returns for 3 years29.2324.77118%
Returns for 5 years51.6553.0997%
Returns for 10 years81.23112.2672%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DOLE15.260.19
+1.26%
Dole plc
NCNO40.450.37
+0.92%
nCino
SGHT3.760.03
+0.80%
Sight Sciences
VICI32.370.25
+0.78%
VICI Properties
SABS3.070.01
+0.33%
SAB Biotherapeutics